FDA Grants Priority Review to Otsuka’s ADHD Drug Centanafadine — Otsuka Pharmaceutical Co., Ltd.

Event summary

Otsuka’s New Drug Application (NDA) for centanafadine, a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI), has been accepted for priority review by the FDA.
The Prescription Drug User Fee Act (PDUFA) target action date is set for July 24, 2026.
Centanafadine demonstrated statistically significant improvements in ADHD symptoms across four pivotal Phase 3 clinical trials involving children, adolescents, and adults.
Common adverse events included decreased appetite, nausea, rash, fatigue, abdominal pain, and somnolence in younger patients, and decreased appetite and headache in adults.

The big picture

Otsuka’s centanafadine represents a novel approach in ADHD treatment, addressing an unmet need for patients who may not respond adequately to current therapies. The FDA’s priority review designation underscores the drug’s potential, but its success will depend on demonstrating long-term efficacy and safety in real-world settings. With approximately 7 million children and 15.5 million adults affected by ADHD in the U.S., centanafadine could capture significant market share if approved.

What we're watching

Approval Timeline: Whether the FDA will meet the July 24, 2026 PDUFA target action date for centanafadine’s approval.
Market Differentiation: How Otsuka positions centanafadine against existing ADHD treatments, leveraging its first-in-class NDSRI mechanism.
Commercialization Strategy: The pace at which Otsuka can scale manufacturing and distribution to meet potential demand if approved.